- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Hudson Bay Capital Management LP Acquires Stake in Nuvalent, Inc.
The hedge fund purchased 15,000 shares of the clinical-stage oncology company.
Mar. 23, 2026 at 8:33am
Got story updates? Submit your updates here. ›
Hudson Bay Capital Management LP acquired a new position in Nuvalent, Inc. (NASDAQ:NUVL) in the 3rd quarter, according to a recent SEC filing. The institutional investor purchased 15,000 shares of the company's stock, valued at approximately $1,297,000.
Why it matters
This investment by Hudson Bay Capital Management, a prominent hedge fund, signals confidence in Nuvalent's potential as a clinical-stage oncology company focused on developing targeted therapies for patients with genetically defined cancers.
The details
According to the filing, Hudson Bay Capital Management acquired the 15,000 shares of Nuvalent during the third quarter. This adds to the growing institutional ownership of the company, which now stands at 97.26% of the total shares outstanding.
- Hudson Bay Capital Management acquired the Nuvalent shares in the 3rd quarter of 2026.
The players
Hudson Bay Capital Management LP
A prominent hedge fund that acquired a new position in Nuvalent, Inc.
Nuvalent, Inc.
A clinical-stage precision oncology company focused on developing targeted therapies for patients with genetically defined cancers.
The takeaway
This investment by Hudson Bay Capital Management underscores the growing investor interest in Nuvalent's pipeline of targeted oncology therapies, which could lead to new treatment options for patients with genetically defined cancers.
